The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): a systematic review and economic model

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): a systematic review and economic model

Background: Alzheimer’s disease (AD) is the most commonly occurring form of dementia. It is predominantly a disease of later life, affecting 5% of those over 65 in the UK. Objectives: Review and update guidance to the NHS in England and Wales on the clinical effectiveness and cost-effectiveness of d...

Full description

Bibliographic Details
Main Authors: M Bond, G Rogers, J Peters, R Anderson, M Hoyle, A Miners, T Moxham, S Davis, P Thokala, A Wailoo, M Jeffreys, C Hyde
Format: Article
Language:English
Published: NIHR Journals Library 2012-04-01
Series:Health Technology Assessment
Subjects:
alzheimer’s disease
acetylcholinesterase inhibitor
donepezil
galantamine
rivastigmine
memantine
systematic review
economic model
quality of life
Online Access:https://doi.org/10.3310/hta16210

Similar Items

Similar Items